FundCanna: Institutional Money (Finally) Finds Cannabis

LOS ANGELES – For years, Cannabis operators have built real businesses without access to the financial infrastructure that real businesses normally rely on. That may finally be starting to change. A San Diego-based Cannabis lender has secured a major new credit facility from a global institutional investment firm, in a deal that underscores a slow but measurable shift in how mainstream capital markets are beginning to view the Cannabis sector.

FundCanna, which describes itself as the leading institutional funding source to the regulated Cannabis industry, announced on May 19, 2026, that it had closed a senior credit facility of up to $60 million. The unnamed investor, which FundCanna declined to identify, manages approximately $40 billion [!] in assets under management. The facility delivers $35 million at close, with the balance available as FundCanna scales its lending portfolio. As part of the same transaction, FundCanna reorganized its wider funding structure, drawing in both returning and new investors and bringing the company’s total capital to roughly $75 million. Based on its historical lending pace, the company says the new structure could support more than $500 million in cumulative funding to Cannabis businesses over the next several years.

Why This Is Unusual

To understand why this deal matters, it helps to understand what has passed for “normal” in Cannabis finance.

Cannabis companies operate in a legal gray area that has made traditional bank lending functionally off the table for most operators. Federal law still classifies Cannabis as a Schedule I controlled substance, even as the Biden and Trump administrations have taken steps toward rescheduling. That federal-state conflict means most banks, even those technically permitted to serve Cannabis businesses, have remained reluctant to extend actual loans.

Cannabis operators have long depended on equity raises, sale-leaseback arrangements, real-estate-backed financing, and short-term private credit often at punishing interest rates. Conventional unsecured lending to operating businesses has remained largely absent from any institutional playbook.

“This is institutional capital entering a part of the market it has historically avoided,” said Adam Stettner, founder and CEO of FundCanna, in the company’s announcement. “That includes both established operators and the broader supply chain that drives the cannabis economy.”

The deal was arranged by investment bank Bryant Park Capital. “What ultimately drove investor interest was FundCanna’s combination of real transaction history, risk management discipline, and demonstrated capital efficiency,” said Joel Magerman, managing partner at Bryant Park Capital, in a statement reported by MJBizDaily.

The Receivables Issue

FundCanna’s pitch to institutional investors rests in large part on a product called ReadyPaid, a business-to-business buy-now-pay-later platform the company launched in August 2025. ReadyPaid is designed to attack one of the Cannabis industry’s most stubborn financial problems: delinquent accounts receivable.

Industry analysts, including Cannabis economist Beau Whitney of Whitney Economics, estimate that unpaid invoices across the U.S. legal Cannabis market have reached nearly $4 billion – a figure that translates to a sector strangling itself with its own cash-flow dysfunction. When nearly one-fifth of revenue is tied up in overdue payments, operators lose the ability to plan or invest. As few as 24% of Cannabis businesses reported being profitable in 2023, according to Whitney Economics data.

ReadyPaid allows wholesale sellers to receive payment upfront while extending buyers flexible repayment terms aligned to their revenue cycles. The platform processes credit decisions in minutes through automated compliance and background checks. According to FundCanna, the platform has processed several million dollars in transactions to date with no reported delinquencies.

With the new facility in place, the company plans to expand ReadyPaid’s reach to larger MSOs and established Cannabis brands focused on scaling their wholesale distribution operations.

Building the Track Record

FundCanna’s argument for institutional credibility is largely built on volume and discipline. The company has originated more than 5,000 transactions and is approaching a $100 million annualized run rate. Its lending model focuses on providing liquidity across the Cannabis supply chain: from MSOs down to manufacturers, distributors, and retailers that have historically had the fewest options when it comes to accessing capital.

Stettner, who has spent more than two decades in business lending, has positioned the company around an underwriting discipline that accounts for the specific volatility of Cannabis markets, including regulatory inconsistency, fragmented data, and the legal peculiarities that separate Cannabis from any other industry. “Cannabis has proven to be a stronger credit market than many expect, but it’s also one of the most difficult markets to get right.”, he noted.

The Broader Context

The FundCanna transaction arrives at a moment when the regulatory and financial backdrop for Cannabis is, however slowly, shifting. Cannabis was reclassified from Schedule I to Schedule III under the Controlled Substances Act by executive order in December 2025, a change that carries meaningful implications for how operators are taxed. For qualifying medical Cannabis companies, the rescheduling removes the application of IRS Section 280E – a  provision that had long forced Cannabis businesses to pay taxes on gross revenue rather than net income, in some cases producing effective tax rates above 70%.

That relief does not extend universally. Recreational operators remain under 280E constraints for now, and full banking reform has yet to materialize legislatively. But the direction of travel is clear enough that some institutional investors appear willing to move ahead of the regulatory finish line.

For FundCanna and for the broader Cannabis industry, the significance of this deal is less about the dollar amount than about who wrote the check. A global firm managing $40 billion in assets does not typically wade into a niche, federally complicated lending market on a whim. The due diligence required to commit to an unsecured Cannabis lending facility represents a meaningful change in how that category of capital perceives the risk-reward equation.

What It Means Going Forward

Cannabis businesses have long operated with one hand tied behind their backs financially, unable to:

• deduct standard operating expenses,
• access conventional bank loans, and
• attract the same debt capital that comparable businesses in other industries take for granted.

Operators who survived did so through:

• ingenuity,
• expensive private financing, and
• sheer persistence.

The FundCanna deal will not solve all of that. Federal prohibition remains a reality. Banking access is still inconsistent. The SAFER Banking Act has stalled repeatedly in Congress, and full resolution of Cannabis’s legal status remains uncertain.

What the transaction does signal is that institutional capital [the kind that moves slowly, carefully, and only after exhaustive analysis] is beginning to treat Cannabis lending as a financeable asset class. That is a different posture than what existed even two years ago.

Ultimately, it remains to be seen what follows… However, this development* could mark a true inflection point or simply an isolated transaction from an unusually bold institutional investor. If other financial institutions follow this strategy, the Cannabis industry’s chronic capital shortage could, for the first time, begin to ease structurally rather than ad hoc way. The operators who have survived this long deserve at least that much.

* Highly Capitalized Network-HCN covers capital markets, investment, and financial developments across the Cannabis and Psychedelics industries. This copy is for informational purposes only and does not constitute financial or investment advice.